Member Info for Babbler2

grrrr why didnt I buy?!?!?

TechFinancials (AIM: TECH), a leading technology provider to financial trading brokers, provides the following trading update ahead of the Group's Interim Results for the six months ended 30 June 2016, which are expected to be announced in the first half of September 2016. The Group is pleased to report that trading in the first half of 2016 has been strong. Revenue has increased by over 30% from US$7.34 million in the first half of 2015 to in excess of US$9.6 million during the first half of 2016. Additionally, operating performance improved substantially compared with the same period in 2015, resulting in EBITDA increasing by over 80% from US$0.55 million to in excess of US$1 million. Asaf Lahav, Group CEO of TechFinancials, said: "We are very pleased with the results for the first half of 2016. During the period our B2B division continued to perform strongly and we are now finally seeing the fruits of our B2C initiatives. Both revenues and EBITDA are substantially up compared with the same period last year leaving the Board increasingly confident about meeting market expectations for the full year."

nice rns here!

Yes you got it wrong imo http://www.bbc.co.uk/news/business-36961287

leak?

Well under the radar here - build a nice amount whilst I can imho dyor etc

Conclusion The financial year ended 31 March 2016 was transformational for the Company in terms of a step change in scale, product and technology breadth, and organisational development. We have a strong foundation as we continue to make progress in the current financial year, with a clear strategy, specific strategic initiatives, an engaged management team and a shared vision: to become the industry's first choice for regenerative biomaterials.

Impressive growth starting: Revenue from North America grew by �1.262 million to �1.808 million, an increase of 231%, driven by a full year of contribution from the acquisition of Southern Lights Biomaterials as well as our organic growth from a broad base of existing customers. Revenue from Asia grew by �0.889 million to �1.175 million, an increase of 311%, our fastest-growing region, driven by customer growth from the existing Southern Lights Biomaterials base.

We address a current opportunity in excess of $1.5bn for collagen and tissue biomaterials applications. Our focused strategy is to strengthen and grow our core biomaterials supply and manufacturing business, and develop finished devices through both internal development and acquired technologies that we will commercialise via licensing and distribution partnerships.

Outlook We have made a positive start to the current financial year and I am emboldened by the knowledge that the positive benefits of having "sticky" revenues from embedded products will ensure about 70% of the Group's ongoing revenues are already, in effect, secured. Our challenges are to win new customers and execute our pipeline in a timely manner; we have invested in personnel to achieve this. Additionally, we are looking to successfully execute our R&D pipeline where the investment that we have made, and continue to make, begins to produce cash flow. ChondroMimetic represents a significant value creating opportunity but to deliver this we need to be smart about how we execute our plan to ensure we are not putting at risk shareholder value. It was through my colleague Kevin Wilson that we had the opportunity to be introduced to Cre8ive with whom we have formed a joint venture. I am very excited by this opportunity because I believe in and trust the people Kevin introduced. The Company has an initial JV Board meeting in Hong Kong in July, and while the scale of the opportunity is significant and exciting, it will take time to gain traction. Consequently, the Board views contributions from the joint venture being realised largely in the years beyond this current one. The Company is on a journey and whilst we have continued our journey positively this year, we require a higher level of momentum as we move on to the next stage in our development as a Company dedicated to enhancing shareholder value. I remain hugely committed to ensuring the success of Collagen Solutions and I know that commitment is shared throughout the Company. I would like to thank all of our employees and my fellow Directors for their hard work and dedication throughout 2015/16. I look forward to updating you further throughout the year. Thank you for your support.

The past year was transformational for the Company in terms of a step change in scale, product and technology breadth, and organisational development. This has given us a strong foundation as we continue to make progress in the current financial year, with clear and specific strategic initiatives, an engaged management team and a shared vision: to become the industry's first choice for regenerative biomaterials."

Results: Financial Highlights Group revenue and other income increased to �3.24 million (2015: �1.04 million), ahead of guidance of �2.8 million in January 2016 Adjusted LBITDA (before separately identifiable items): �410,016 (2015: �689,816) Net cash balances at 31 March 2016: �2.49 million (2015: �3.39 million)

scrap that - found it! http://ir.collagensolutions.com/content/investors/latest_results.asp

annual results posted today? Still cant see on their site... be interesting read!

It was just waiting for me to get back from holiday ;) Nice to see... want to load up here. It will pop one day imo. Shhhhhh... ;)

nice news here... should do well in results?

Order filling perhaps... Time will tell. Needs a bit more volume. Next news will hopefully see this fly.

and the seller who sold £62k pre last rns @ 8p. Ouch... could have sold at 10p! :D

we have a bulk buyer - look at the trades... 3x100k and 1x 130k all at 9.5. Someone being allowed in... imo

still cant believe people sell after yesterdays rns - but guess de-risking if bought at 6p is good trading. I would probably do the same lol. Holiday money etc etc. Cant see this below 10 for much longer imo. Wish I had more funds... soon...